# Low-Dose Naltrexone (LDN): A Patient Guide **Prepared by:** Pedro Cheung MD **Last Updated:** May 2026 **Prepared for Patient Education | Based on Current Medical Evidence (2025)** --- > **Important Notice:** Low-dose naltrexone is prescribed **off-label** — meaning it has not been approved by the U.S. Food and Drug Administration (FDA) for the conditions described in this handout. All decisions about whether LDN is appropriate for you should be made in close consultation with your healthcare provider. --- ## What Is Naltrexone? Naltrexone is a medication that has been FDA-approved since the 1980s to help people recover from opioid and alcohol addiction. At its standard dose (50–100 mg/day), it completely blocks opioid receptors in the brain, eliminating the pleasurable effects of opioids and alcohol.[^1] **Low-dose naltrexone (LDN)** refers to much smaller amounts — typically **1.5 to 4.5 mg per day** — that appear to work through entirely different biological mechanisms than the standard dose. At these low doses, LDN is being studied and used off-label for a growing number of chronic inflammatory, autoimmune, and neurological conditions.[^2] --- ## How Does LDN Work? Researchers believe LDN works through two main pathways: **1. Endorphin Boosting ("Rebound Effect")** At low doses, LDN briefly blocks opioid receptors for only 4–6 hours. The brain responds to this brief blockade by producing _more_ opioid receptors and increasing its own natural endorphins (your body's natural pain-relieving and mood-lifting chemicals) for the following 18–24 hours. This rebound effect may reduce pain and improve mood.[^3] **2. Anti-Inflammatory / Immune-Modulating Effects** LDN also appears to act on specialized immune cells in the brain called **microglia**. When overactivated, microglia produce inflammatory chemicals (cytokines) that are thought to drive neuroinflammation — the brain-based inflammation associated with symptoms like pain, fatigue, and "brain fog." LDN may reduce microglial overactivation and dampen this inflammatory response.[^4] **3. TRPM3 Ion Channel Restoration (Relevant to ME/CFS)** Emerging research has identified a specific molecular mechanism particularly relevant to ME/CFS. A protein channel called **TRPM3** — involved in pain sensation, immune defense, and calcium signaling — is dysfunctional in the natural killer (NK) cells of ME/CFS patients. Laboratory studies show that naltrexone can restore normal TRPM3 function in these immune cells, which may partially explain LDN's benefit in ME/CFS.[^5][^6] --- ## Off-Label Conditions Being Studied LDN is being used or studied for a wide range of conditions, though the strength of evidence varies considerably. **None of the following are FDA-approved indications for LDN:** |Condition|Current Evidence Level| |---|---| |**Fibromyalgia**|Moderate — multiple small RCTs, 1 meta-analysis| |**ME/CFS (Myalgic Encephalomyelitis/Chronic Fatigue Syndrome)**|Limited — case series, retrospective studies, ongoing RCTs| |**Long COVID / Post-COVID Fatigue Syndrome**|Emerging — retrospective cohort studies, RCT in progress| |Crohn's disease|Limited — small pilot RCTs| |Multiple sclerosis|Limited — conflicting small trials| |Diabetic peripheral neuropathy|Limited — one small comparative trial| |Depression (treatment-augmentation)|Very limited — one pilot study| |POTS (Postural Orthostatic Tachycardia Syndrome)|Very limited — small case series| |Mast Cell Activation Syndrome (MCAS)|Anecdotal / case reports only| |Chronic pain conditions (general)|Retrospective cohort data| --- ## Evidence for Benefit: What Does the Research Say? ### Fibromyalgia The best evidence for LDN exists in fibromyalgia. A **2024 systematic review and meta-analysis** pooled results from 4 randomized controlled trials (RCTs) with 222 fibromyalgia patients. It found that LDN produced a **statistically significant reduction in pain scores** and improvements in pressure pain threshold compared to placebo. LDN was associated with vivid dreams and nausea more often than placebo, but there were **no significant differences in serious adverse events**.[^7] Earlier landmark work by Dr. Jarred Younger (Stanford/University of Alabama) also demonstrated benefits: - A 2009 single-blind crossover pilot study found LDN (4.5 mg/day) significantly reduced pain, fatigue, and stress.[^8] - A 2013 double-blind, randomized, placebo-controlled crossover trial showed approximately **30% pain reduction in about 60% of participants**, along with improved mood and life satisfaction.[^9] A 2025 real-world retrospective cohort study of 93 chronic pain patients (including 27 with fibromyalgia) found **53.8% of patients reported subjective symptom improvement**, most commonly in pain and fatigue. No serious adverse effects were reported.[^10] ### ME/CFS (Myalgic Encephalomyelitis / Chronic Fatigue Syndrome) ME/CFS is a serious, complex, and poorly understood illness characterized by: - Profound, debilitating fatigue not relieved by rest - **Post-exertional malaise (PEM)** — worsening of symptoms after physical or mental activity - Unrefreshing sleep - Cognitive dysfunction ("brain fog") - Orthostatic intolerance (dizziness upon standing) There are currently **no FDA-approved treatments** for ME/CFS. LDN is one of several off-label options being explored. **What the evidence shows so far:** - A **retrospective study of 218 ME/CFS patients** found approximately **74% experienced some benefit** from LDN, with improvements in at least two or more symptoms.[^11] - A **2020 BMJ case series** of 3 ME/CFS patients described responses ranging from life-changing improvement to partial symptom reduction at doses of 4–12 mg.[^12] - A 2021 study from Griffith University (Australia) demonstrated that ME/CFS patients currently taking LDN had **restored TRPM3 channel function** in their NK immune cells — providing a possible biological explanation for clinical benefit.[^5] - A 2024 review article from Goethe University proposed that widespread TRPM3 dysfunction in ME/CFS may affect not just immune cells but also small nerve fibers and the brain, and that LDN may offer benefit by targeting this pathway.[^6] - A **2024 retrospective cohort study** found LDN was associated with a **relative hazard of improvement of 5.04** (95% CI: 1.22–20.77) compared to physical therapy alone in post-COVID patients with fatigue syndrome symptoms overlapping with ME/CFS.[^13] **Important caveat:** The ME/CFS evidence is still largely based on retrospective studies, case reports, and mechanistic laboratory research. **No large, published RCT has yet confirmed efficacy specifically in ME/CFS.** However, trials are now underway (see "What's Coming Next" below). ### Long COVID / Post-COVID Fatigue Syndrome A significant proportion of Long COVID patients present with fatigue, post-exertional malaise, brain fog, and pain very similar to ME/CFS. The same mechanisms driving LDN's potential benefit in ME/CFS may apply. Early retrospective data and clinical experience suggest benefit, and the first randomized controlled trial is now underway (see below).[^14] --- ## ME/CFS and LDN: A Closer Look ME/CFS affects an estimated **0.68–0.89% of the population** worldwide (approximately 1–3 million Americans), with women affected 1.5–2 times more than men.[^15] Up to **91% of patients in the U.S. remain undiagnosed**, and even those diagnosed often receive inadequate or even harmful care.[^16] **Why ME/CFS patients and their doctors are interested in LDN:** - No other medication has proven reliably effective in controlled trials for ME/CFS - LDN is inexpensive, orally administered, and has a favorable safety profile - It targets neuroinflammation and immune dysregulation — two mechanisms increasingly linked to ME/CFS pathophysiology - It may address the NK cell dysfunction consistently found in ME/CFS patients - Clinical experience from ME/CFS specialists (including Dr. Melanie Hoppers at the Bateman Horne Center and Dr. Kenny De Meirleir) suggests that roughly **60–75% of ME/CFS patients trying LDN experience meaningful improvement** in pain, fatigue, and/or brain fog[^17] **Realistic expectations for ME/CFS patients:** - LDN is **not a cure** — it may reduce the burden of symptoms but rarely eliminates ME/CFS entirely - Full effects may take **2–3 months** to appear - Response is highly individual — some patients improve substantially; others notice little benefit - Dosing often requires careful, personalized titration --- ## Dosing: How Is LDN Taken? Because LDN is not FDA-approved for these conditions, doses are not standardized. General clinical practice includes: - **Starting dose:** 1–1.5 mg/day (sometimes as low as 0.5 mg in very sensitive ME/CFS patients) - **Titration:** Increase slowly every 2–4 weeks as tolerated - **Target dose:** Most commonly **3–4.5 mg/day** for ME/CFS and fibromyalgia - **Maximum studied dose:** Up to 9 mg/day in some fibromyalgia research; doses above 5 mg have diminishing benefit for ME/CFS in clinical experience - **Timing:** Usually taken at bedtime, though patients with sleep disruption may do better taking it in the morning[^17] - **Form:** LDN must be **compounded** by a specialty pharmacy, as it is not commercially available at low doses > **"Start low, go slow"** is the guiding principle. Your doctor will work with you to find the dose that balances benefit and tolerability. --- ## Potential Benefits (Summary) Based on available evidence and clinical experience, LDN may provide the following benefits for qualifying patients: - ✅ Reduction in chronic pain - ✅ Decreased fatigue - ✅ Improvement in cognitive symptoms ("brain fog") - ✅ Better sleep quality (in some patients) - ✅ Reduced neuroinflammation - ✅ Improved mood and overall quality of life - ✅ Possible immune system modulation (particularly relevant in ME/CFS) - ✅ Favorable long-term safety profile --- ## Side Effects and Risks LDN is considered to have a **favorable safety profile**, and serious adverse events have not been reported at clinical doses in any trial to date.[^7][^10] ### Common Side Effects (usually temporary, occurring early in treatment) - **Vivid or unusual dreams** — the most commonly reported side effect - **Insomnia or sleep disturbance** — may improve with morning dosing - **Nausea** — usually mild and transient - **Headache** - **Fatigue or dizziness** (paradoxically, especially early in treatment) - **Decreased appetite** ### Less Common Side Effects - Anxiety - Mood changes or irritability - Muscle or joint pain - Stomach discomfort or diarrhea ### Rare but Serious Side Effects (reported at standard doses; possible at any dose) - Allergic reactions (rash, difficulty breathing) - Elevated liver enzymes — liver monitoring may be appropriate for long-term use - Depression or worsening mood - Rapid heart rate or blood pressure changes > **Contact your doctor promptly** if you experience jaundice (yellowing of skin/eyes), severe abdominal pain, significant mood changes, or allergic reactions. --- ## Important Warnings and Contraindications ### ⚠️ ABSOLUTE CONTRAINDICATIONS — Do NOT take LDN if: - You are currently taking **any opioid pain medication** (e.g., morphine, oxycodone, hydrocodone, tramadol, codeine, fentanyl, buprenorphine, methadone). LDN will immediately precipitate **opioid withdrawal**, which can be severe and dangerous. - You are in **acute opioid withdrawal**. - You have a known **allergy to naltrexone**. - You have **acute hepatitis or liver failure**. ### ⚠️ USE WITH CAUTION — Discuss carefully with your doctor if you: - Have **kidney or liver disease** — dose adjustment may be needed; liver function tests should be monitored - Are **pregnant or breastfeeding** — safety data are limited; discuss risks and benefits with your obstetrician - Are scheduled for **surgery or a procedure** requiring opioid anesthesia — LDN must be stopped in advance (typically 72 hours before) - Have a history of **opioid use disorder** — special considerations apply ### ⚠️ KEY DRUG INTERACTIONS LDN can interact with several medications. Always provide your full medication list to your doctor and pharmacist: |Drug/Drug Class|Concern| |---|---| |**All opioid medications**|Risk of acute withdrawal — absolute contraindication| |**Tramadol**|Some experts consider this a relative rather than absolute contraindication; discuss with your prescriber| |**Warfarin (Coumadin)**|LDN may alter blood thinning effects — closer INR monitoring needed| |**Immunosuppressants**|Theoretical interaction given immune-modulating properties of LDN| |**Certain antidepressants**|Possible interactions — inform your doctor| |**Thioridazine**|Potential interaction| |**Alcohol**|Use cautiously; LDN may reduce its rewarding effects| --- ## How to Obtain LDN Because LDN is not commercially available in low doses, it requires a **compounding pharmacy prescription**: 1. Ask your doctor to prescribe LDN at your agreed-upon starting dose 2. The prescription is filled at a **compounding pharmacy** that prepares custom doses 3. **Cost:** Generally inexpensive — typically $30–$60/month, as compounding costs are modest. Most insurance plans do **not** cover compounded LDN; check with your insurer. 4. Both capsule and liquid forms are available; liquid forms allow for very precise low-dose titration, which is helpful early in treatment > **Important:** Quality varies between compounding pharmacies. Ask your doctor or pharmacist to recommend an accredited compounding pharmacy (look for PCAB accreditation). --- ## What's Coming Next: Ongoing Research Research into LDN for ME/CFS and related conditions is accelerating: - A **Phase II randomized, double-blind, placebo-controlled trial** (NCT05430152) is underway in British Columbia, Canada, evaluating LDN (titrated to 4.5 mg/day) specifically for post-COVID fatigue syndrome meeting ME/CFS criteria. Results are expected to significantly advance the evidence base.[^14] - Additional mechanistic studies investigating LDN's effects on TRPM3 channels and NK cell function in ME/CFS are ongoing at Griffith University, Australia. - Fibromyalgia trials continue to accumulate evidence, with researchers calling for larger, well-powered trials to confirm existing findings.[^7] --- ## Questions to Ask Your Doctor Before starting LDN, consider discussing: - [ ] Am I a good candidate for LDN given my current medications and health conditions? - [ ] What starting dose do you recommend, and how will we titrate? - [ ] Should I have any baseline lab work (liver function, etc.) before starting? - [ ] Which compounding pharmacy do you recommend? - [ ] How long should I try LDN before deciding if it's helping? - [ ] What symptoms would prompt you to stop LDN? - [ ] How does LDN fit into my overall treatment plan for ME/CFS/fibromyalgia? --- ## Bottom Line Low-dose naltrexone is an inexpensive, generally well-tolerated, and biologically plausible treatment option for ME/CFS, fibromyalgia, and related conditions characterized by neuroinflammation, chronic pain, and immune dysfunction. The best evidence currently exists for fibromyalgia, where it has been shown in multiple controlled trials to reduce pain by approximately 30% in 60% of patients. Evidence for ME/CFS is promising but still primarily from retrospective data and mechanistic studies — larger randomized trials are needed and underway. LDN is not right for everyone, carries real contraindications (especially if you take opioids), and requires careful, personalized dosing. However, for patients with limited treatment options and significant symptom burden, it represents one of the more scientifically grounded off-label therapies currently available. **Always work with a knowledgeable clinician before starting LDN.** --- ## Footnotes and References [^1]: Memorial Sloan Kettering Cancer Center. "Low-dose naltrexone." [https://mskcc.org/cancer-care/integrative-medicine/herbs/low-dose-naltrexone](https://mskcc.org/cancer-care/integrative-medicine/herbs/low-dose-naltrexone) (Updated 2022). [^2]: Verywellhealth. "Low-Dose Naltrexone and What Science Says About Its Benefits." [https://www.verywellhealth.com/how-drugs-work-in-your-body-1124115](https://www.verywellhealth.com/how-drugs-work-in-your-body-1124115) [^3]: Health Rising. "Low Dose Naltrexone (LDN) Fibromyalgia and Chronic Fatigue Syndrome Resource Center." [https://www.healthrising.org/treating-chronic-fatigue-syndrome/drugs/low-dose-naltrexone-ldn-fibromyalgia-chronic-fatigue-syndrom/](https://www.healthrising.org/treating-chronic-fatigue-syndrome/drugs/low-dose-naltrexone-ldn-fibromyalgia-chronic-fatigue-syndrom/) [^4]: Hoppers M. "Exploring the Potential of Low Dose Naltrexone (LDN) for ME/CFS and Beyond." Bateman Horne Center. September 2024. [https://batemanhornecenter.org/exploring-the-potential-of-low-dose-naltrexone-for-me-cfs/](https://batemanhornecenter.org/exploring-the-potential-of-low-dose-naltrexone-for-me-cfs/) [^5]: Cabanas H, et al. "Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment." _Frontiers in Immunology._ 2021;12:687806. DOI: [10.3389/fimmu.2021.687806](https://doi.org/10.3389/fimmu.2021.687806). Retrieved via PubMed (PMID: 34326841). [^6]: Löhn M, Wirth KJ. "Potential pathophysiological role of the ion channel TRPM3 in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and the therapeutic effect of low-dose naltrexone." _Journal of Translational Medicine._ 2024;22(1):630. DOI: [10.1186/s12967-024-05412-3](https://doi.org/10.1186/s12967-024-05412-3). Retrieved via PubMed (PMID: 38970055). [^7]: Almutairi M, et al. "Efficacy and safety of low-dose naltrexone for the management of fibromyalgia: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis." _Korean Journal of Pain._ 2024. DOI: [10.3344/kjp.24202](https://doi.org/10.3344/kjp.24202). (Via epain.org) [^8]: Younger J, Mackey S. "Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study." _Pain Medicine._ 2009;10(4):663–72. [^9]: Younger J, Noor N, McCue R, et al. "Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels." _Arthritis & Rheumatism._ 2013;65(2):529–538. [^10]: Aalto H, Paul S, McEwen V. "Real World Effectiveness and Tolerability of Low Dose Naltrexone to Treat Chronic Pain." _Journal of Pain Research._ 2025. [https://www.dovepress.com/real-world-effectiveness-and-tolerability-of-low-dose-naltrexone-to-tr-peer-reviewed-fulltext-article-JPR](https://www.dovepress.com/real-world-effectiveness-and-tolerability-of-low-dose-naltrexone-to-tr-peer-reviewed-fulltext-article-JPR) [^11]: Retrospective study of 218 ME/CFS patients cited in: Bolton MJ, Chapman BP, Van Marwijk H. "Low-dose naltrexone as a treatment for chronic fatigue syndrome." _BMJ Case Reports._ 2020;13(1):e232502. DOI: [10.1136/bcr-2019-232502](https://doi.org/10.1136/bcr-2019-232502). Retrieved via PubMed (PMID: 31911410). [^12]: Bolton MJ, Chapman BP, Van Marwijk H. "Low-dose naltrexone as a treatment for chronic fatigue syndrome." _BMJ Case Reports._ 2020;13(1):e232502. DOI: [10.1136/bcr-2019-232502](https://doi.org/10.1136/bcr-2019-232502). Retrieved via PubMed (PMID: 31911410). [^13]: Tamariz L, Bast E, Klimas N, Palacio A. "Low-dose Naltrexone Improves post-COVID-19 condition Symptoms." _Clinical Therapeutics._ 2024;46(3):e101–e106. DOI: [10.1016/j.clinthera.2023.12.009](https://doi.org/10.1016/j.clinthera.2023.12.009). Retrieved via PubMed (PMID: 38267326). [^14]: Naik H, et al. "Low-dose naltrexone for post-COVID fatigue syndrome: a study protocol for a double-blind, randomised trial in British Columbia." _BMJ Open._ 2024;14(5):e085272. DOI: [10.1136/bmjopen-2024-085272](https://doi.org/10.1136/bmjopen-2024-085272). Retrieved via PubMed (PMID: 38740499). [^15]: Lim EJ, et al. "Systematic review and meta-analysis of the prevalence of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME)." _Journal of Translational Medicine._ 2020;18:100. (Via Consensus: [link](https://consensus.app/papers/details/0e803caa03ef5211b87f64d5b4d7914e/)) [^16]: Bateman L, et al. "Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Essentials of Diagnosis and Management." _Mayo Clinic Proceedings._ 2021;96(10):2629–2645. (Via Consensus: [link](https://consensus.app/papers/details/4539ab8546325192b4df8bb56d4a11f2/)) [^17]: Hoppers M. Bateman Horne Center, 2024; and Health Rising ME/CFS LDN Resource Center citing Dr. De Meirleir's clinical protocol. --- _This handout is intended for educational purposes and does not constitute medical advice. Please consult your healthcare provider before starting, stopping, or changing any medication._ _Evidence summary current as of May 2025._